A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

Prior treatment

• Other malignancies within the past 5 years or concurrent malignancy.
• Previous or current central nervous system metastases.
• Arterial thrombotic or embolic events within 6 months before enrollment.

Other illness

• Known history of severe hypersensitivity reaction to any monoclonal antibody.
• Hypertension that cannot be well controlled with antihypertensive medication.
• Poorly controlled cardiac symptoms or heart disease.
• Known hereditary or acquired bleeding disorders (e.g., coagulopathy) or thrombotic tendency.
• Any other condition that, in the investigator's judgment, may affect the study results or lead to premature termination of the study.

Other

• Known intrahepatic cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, mixed hepatocellular carcinoma, or fibrolamellar hepatocellular carcinoma.
• Clinically symptomatic moderate or severe ascites requiring therapeutic paracentesis or drainage.

• Subjects who voluntarily participate in this study and sign the informed consent form.
• Age from 18 to 70, male or female.
• Histopathologically/cytologically confirmed or clinically diagnosed with hepatocellular carcinoma (HCC).
• At least one measurable lesion based on RECIST v1.1.
• No prior systemic antitumor therapy for HCC.
• ECOG Performance Status (PS) score of 0-1.
• Child-Pugh liver function class A.
• Expected survival at least 3 months.
• Adequate organ function.
• Blood pregnancy negative (women of childbearing age) and non-breastfeeding, effective contraception.